View Item 

Show simple item record

Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo
dc.contributor.authorNieman, M. T.en_US
dc.contributor.authorBurke, Fernanda Ferraccioli Marquesen_US
dc.contributor.authorWarnock, Marken_US
dc.contributor.authorZhou, Y.en_US
dc.contributor.authorSweigart, J.en_US
dc.contributor.authorChen, A.en_US
dc.contributor.authorRicketts, D.en_US
dc.contributor.authorLucchesi, Benedict Roberten_US
dc.contributor.authorChen, Z.en_US
dc.contributor.authorDi Cera, E.en_US
dc.contributor.authorHilfinger, John M.en_US
dc.contributor.authorKim, J. S.en_US
dc.contributor.authorMosberg, Henry I.en_US
dc.contributor.authorSchmaier, Alvin H.en_US
dc.date.accessioned2010-06-01T20:54:00Z
dc.date.available2010-06-01T20:54:00Z
dc.date.issued2008-05en_US
dc.identifier.citationNIEMAN, M. T.; BURKE, F.; WARNOCK, M.; ZHOU, Y.; SWEIGART, J.; CHEN, A.; RICKETTS, D.; LUCCHESI, B. R.; CHEN, Z.; DI CERA, E.; HILFINGER, J.; KIM, J. S.; MOSBERG, H. I.; SCHMAIER, A. H. (2008). "Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo ." Journal of Thrombosis and Haemostasis 6(5): 837-845. <http://hdl.handle.net/2027.42/73996>en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73996
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18315550&dopt=citationen_US
dc.format.extent524717 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2008 International Society on Thrombosis and Haemostasisen_US
dc.subject.otherBradykininen_US
dc.subject.otherThrombinen_US
dc.subject.otherThrombin Inhibitoren_US
dc.subject.otherThrombostatinen_US
dc.subject.otherPlateletsen_US
dc.subject.otherRPPGFen_US
dc.titleThrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivoen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum§ Department of Pharmacology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationother* Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OHen_US
dc.contributor.affiliationother† College of Pharmacyen_US
dc.contributor.affiliationother† Department of Medicineen_US
dc.contributor.affiliationother¶ Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MOen_US
dc.contributor.affiliationother** TSRL Inc., Ann Arbor, MI, USAen_US
dc.identifier.pmid18315550en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73996/1/j.1538-7836.2008.02937.x.pdf
dc.identifier.doi10.1111/j.1538-7836.2008.02937.xen_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferenceYusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494 – 502.en_US
dc.identifier.citedreferenceMatetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Ores H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171 – 5.en_US
dc.identifier.citedreferenceAngiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F, Banuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541 – 8.en_US
dc.identifier.citedreferenceWiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001 – 15.en_US
dc.identifier.citedreferenceHasan AA, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 1996; 94: 517 – 28.en_US
dc.identifier.citedreferenceHasan AA, Warnock M, Nieman M, Srikanth S, Mahdi F, Krishnan R, Tulinsky A, Schmaier AH. Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol 2003; 285: H183 – 93.en_US
dc.identifier.citedreferenceNieman MT, Warnock M, Hasan AA, Mahdi F, Lucchesi BR, Brown NJ, Murphey LJ, Schmaier AH. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther 2004; 311: 492 – 501.en_US
dc.identifier.citedreferenceNieman MT, Pagan-Ramos E, Warnock M, Krijanovski Y, Hasan AA, Schmaier AH. Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. FEBS Lett 2005; 579: 25 – 9.en_US
dc.identifier.citedreferenceMurphey LJ, Malave HA, Petro J, Biaggioni I, Byrne DW, Vaughan DE, Luther JM, Pretorius M, Brown NJ. Bradykinin and its metaboliste bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. J Pharmacol Exp Ther 2006; 318: 128701292.en_US
dc.identifier.citedreferenceBurke FM, Warnock M, Schmaier AH, Mosberg HI. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation. Chem Biol Drug Des 2006; 68: 235 – 8.en_US
dc.identifier.citedreferenceNieman MT, Schmaier AH. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 2007; 46: 8603 – 10.en_US
dc.identifier.citedreferencePineda AO, Carrell CJ, Bush LA, Prasad S, Caccia S, Chen ZW, Mathews FS, Di Cera E. Molecular dissection of Na+ binding to thrombin. J Biol Chem 2004; 279: 31842 – 53.en_US
dc.identifier.citedreferenceOtwinowski Z, Minor W. Processing of X-ray diffractin data collected in oscillation mode. Methods Enzymol 1997; 276: 307 – 26.en_US
dc.identifier.citedreferenceBailey S. The CCP4 Suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994; 50: 760 – 3.en_US
dc.identifier.citedreferenceBrunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Raed RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54: 905 – 21.en_US
dc.identifier.citedreferenceMorris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. Proteins 1992; 12: 345 – 64.en_US
dc.identifier.citedreferenceRowland M, Tozer T. Clinical Pharmacokinetics Concepts and Application, 2nd edn. Philadelphia, PA: Lea and Febiger, 1989.en_US
dc.identifier.citedreferenceCleary DB, Ehringer WD, Maurer MC. Establishing the inhibitory effects of bradykinin on thrombin. Arch Biochem Biophys 2003; 410: 96 – 106.en_US
dc.identifier.citedreferenceBode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1: 426 – 71.en_US
dc.identifier.citedreferenceKuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999; 38: 4572 – 85.en_US
dc.identifier.citedreferenceSambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000; 275: 6819 – 23.en_US
dc.identifier.citedreferenceHasan AA, Warnock M, Srikanth S, Schmaier AH. Developing peptide inhibitors to thrombin activation of platelets from bradykinin analogs. Thromb Res 2001; 104: 451 – 65.en_US
dc.identifier.citedreferenceAntman EM, Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624 – 30.en_US
dc.identifier.citedreferenceBah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E. Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci USA 2007; 104: 11603 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1538-7836.2008.02937.x.pdf
Size:
512.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.